Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel Free PRAX Stock Alerts

Praxis Precision Medicines (PRAX) Financials

Praxis Precision Medicines logo
$320.53 -22.05 (-6.44%)
Closing price 04:00 PM Eastern
Extended Trading
$318.55 -1.98 (-0.62%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Praxis Precision Medicines

Annual Income Statements for Praxis Precision Medicines

This table shows Praxis Precision Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -41 -70 -167 -214 -123 -183 -303
Consolidated Net Income / (Loss)		 -36 -62 -167 -214 -123 -183 -303
Net Income / (Loss) Continuing Operations		 -36 -62 -167 -214 -123 -183 -303
Total Pre-Tax Income 		-36 -62 -167 -214 -123 -183 -303
Total Operating Income		 -36 -62 -167 -215 -126 -200 -326
Total Gross Profit		 0.00 0.00 0.00 0.00 2.45 8.55 0.00
Total Revenue		 0.00 0.00 0.00 0.00 2.45 8.55 0.00
Operating Revenue		 - - - 0.00 - - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 62 167 215 129 209 326
Selling, General & Admin Expense		 6.23 17 47 60 42 56 59
Research & Development Expense		 30 45 120 155 87 152 267
Total Other Income / (Expense), net		 0.19 0.28 0.27 0.96 3.10 17 23
Other Income / (Expense), net		 - 0.14 - 0.96 3.10 17 23
Basic Earnings per Share		 ($26.60) ($7.86) ($3.94) ($69.65) ($18.69) ($10.21) ($13.48)
Weighted Average Basic Shares Outstanding		 1.53M 8.95M 42.45M 3.07M 6.59M 17.91M 22.50M
Diluted Earnings per Share		 ($26.60) ($7.86) ($3.94) ($69.65) ($18.69) ($10.21) ($13.48)
Weighted Average Diluted Shares Outstanding		 1.53M 8.95M 42.45M 3.07M 6.59M 17.91M 22.50M
Weighted Average Basic & Diluted Shares Outstanding		 1.53M 8.95M 45.49M 52.39M 13.24M 20.16M 27.85M

Quarterly Income Statements for Praxis Precision Medicines

This table shows Praxis Precision Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Consolidated Net Income / (Loss)		 -25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Net Income / (Loss) Continuing Operations		 -25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Total Pre-Tax Income 		-25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Total Operating Income		 -26 -28 -42 -37 -57 -64 -75 -76 -78 -97 -106
Total Gross Profit		 0.47 0.52 0.43 0.36 0.30 7.46 0.00 0.00 0.00 - 0.00
Total Revenue		 0.47 0.52 0.43 0.36 0.30 7.46 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 26 28 42 38 57 71 75 76 78 97 106
Selling, General & Admin Expense		 8.72 9.93 15 11 15 15 14 13 13 20 28
Research & Development Expense		 17 18 27 27 42 56 61 63 66 78 78
Total Other Income / (Expense), net		 0.88 0.93 2.33 4.81 4.93 5.28 5.43 4.94 4.43 8.13 13
Other Income / (Expense), net		 0.88 0.93 2.33 4.81 4.93 5.28 5.43 4.94 4.43 8.13 13
Basic Earnings per Share		 ($2.72) ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20)
Weighted Average Basic Shares Outstanding		 9.04M 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M
Diluted Earnings per Share		 ($2.72) ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20)
Weighted Average Diluted Shares Outstanding		 9.04M 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M
Weighted Average Basic & Diluted Shares Outstanding		 128.55M 13.24M 17.11M 17.76M 18.64M 20.16M 20.37M 21.05M 25.01M 27.85M 27.88M

Annual Cash Flow Statements for Praxis Precision Medicines

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 27 252 -157 -78 20 134 142
Net Cash From Operating Activities		 -33 -53 -125 -185 -111 -132 -249
Net Cash From Continuing Operating Activities		 -33 -53 -125 -185 -110 -131 -250
Net Income / (Loss) Continuing Operations		 -36 -62 -167 -214 -123 -183 -303
Consolidated Net Income / (Loss)		 -36 -62 -167 -214 -123 -183 -303
Depreciation Expense		 0.04 0.05 0.18 0.42 0.43 0.36 0.14
Amortization Expense		 - 0.00 2.09 1.00 0.05 -5.01 -3.59
Non-Cash Adjustments To Reconcile Net Income		 1.31 5.91 24 29 26 45 33
Changes in Operating Assets and Liabilities, net		 0.75 3.24 16 -1.78 -13 12 24
Net Cash From Investing Activities		 -0.10 0.00 -141 97 39 -248 -311
Net Cash From Continuing Investing Activities		 -0.10 0.00 -141 97 39 -248 -311
Purchase of Property, Plant & Equipment		 -0.10 0.00 -1.05 -0.44 -0.05 0.00 -0.06
Purchase of Investments		 - 0.00 -164 -83 0.00 -372 -624
Sale and/or Maturity of Investments		 - 0.00 25 180 39 123 313
Net Cash From Financing Activities		 60 304 108 10 92 514 702
Net Cash From Continuing Financing Activities		 60 304 108 10 92 514 702
Issuance of Common Equity		 0.00 201 106 11 92 515 704
Other Financing Activities, net		 0.00 0.09 2.45 -0.26 -0.14 -0.31 -2.09

Quarterly Cash Flow Statements for Praxis Precision Medicines

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -23 -20 71 -6.84 24 47 -50 -8.15 -7.89 208 179
Net Cash From Operating Activities		 -23 -24 -21 -27 -28 -56 -53 -55 -65 -76 -86
Net Cash From Continuing Operating Activities		 -24 -23 -21 -27 -28 -56 -53 -54 -65 -77 -86
Net Income / (Loss) Continuing Operations		 -25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Consolidated Net Income / (Loss)		 -25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Depreciation Expense		 0.11 0.11 0.11 0.11 0.09 0.05 0.05 0.05 0.02 0.03 0.04
Amortization Expense		 - - -0.08 -1.53 -2.01 -1.39 -1.23 -0.99 -0.71 -0.67 -0.66
Non-Cash Adjustments To Reconcile Net Income		 4.80 7.12 17 6.11 13 8.82 9.04 8.58 7.71 7.90 17
Changes in Operating Assets and Liabilities, net		 -3.92 -3.78 1.47 0.72 14 -4.92 8.74 9.06 1.85 4.29 -10
Net Cash From Investing Activities		 - -0.05 -91 -196 50 -11 -51 18 50 -328 -344
Net Cash From Continuing Investing Activities		 -0.05 - -91 -196 50 -11 -51 18 50 -328 -344
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 0.01 - - -0.06
Purchase of Investments		 - - -91 -199 -12 -69 -117 -41 -75 -390 -487
Sale and/or Maturity of Investments		 - - 0.00 3.00 62 59 66 59 126 62 143
Net Cash From Financing Activities		 - 4.13 183 216 1.44 114 54 29 6.76 613 609
Net Cash From Continuing Financing Activities		 - 4.13 183 216 1.44 114 54 29 6.76 613 609
Issuance of Common Equity		 0.00 4.13 183 216 1.44 114 55 29 6.81 613 621
Other Financing Activities, net		 -0.00 -0.01 0.01 -0.01 -0.00 -0.16 -0.64 -0.58 -0.05 -0.82 -12

Annual Balance Sheets for Praxis Precision Medicines

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 48 303 293 115 88 483 938
Total Current Assets		 45 302 287 111 85 404 611
Cash & Equivalents		 45 297 139 62 81 215 357
Short-Term Investments		 - 0.00 137 39 0.00 177 242
Prepaid Expenses		 0.68 5.72 11 10 3.58 12 12
Plant, Property, & Equipment, net		 0.13 0.08 1.21 0.97 0.59 0.23 0.15
Total Noncurrent Assets		 2.07 0.77 4.13 3.32 2.48 79 327
Long-Term Investments		 - - - - 0.00 77 327
Other Noncurrent Operating Assets		 2.07 0.77 4.13 3.32 2.48 1.55 0.09
Total Liabilities & Shareholders' Equity		 48 303 293 115 88 483 938
Total Liabilities		 7.58 16 42 39 18 38 60
Total Current Liabilities		 6.82 16 38 34 16 38 60
Accounts Payable		 2.67 4.09 11 15 5.82 13 25
Accrued Expenses		 3.46 11 27 16 7.42 24 35
Other Current Liabilities		 0.70 0.76 0.81 1.01 1.13 1.26 0.11
Total Noncurrent Liabilities		 0.76 0.00 3.50 4.68 2.53 0.11 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -81 287 251 76 70 445 878
Total Preferred & Common Equity		 -81 287 251 76 70 445 878
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -81 287 251 76 70 445 878
Common Stock		 0.00 437 568 607 724 1,282 2,018
Retained Earnings		 -81 -150 -317 -531 -654 -837 -1,140
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.18 -0.17 0.00 0.65 0.56

Quarterly Balance Sheets for Praxis Precision Medicines

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 137 98 133 107 250 441 416 479 453 396 1,460
Total Current Assets		 132 94 130 103 212 357 360 334 307 274 798
Cash & Equivalents		 62 81 124 101 152 145 169 166 157 150 536
Short-Term Investments		 61 4.98 0.00 0.00 55 207 188 162 144 118 251
Prepaid Expenses		 8.57 8.58 5.53 2.24 4.39 4.84 3.02 5.58 5.30 6.69 11
Plant, Property, & Equipment, net		 1.08 0.87 0.76 0.70 0.48 0.37 0.28 0.25 0.26 0.17 0.17
Total Noncurrent Assets		 3.51 3.12 2.91 2.70 38 84 56 145 146 122 662
Long-Term Investments		 - - - - 36 82 54 144 145 122 661
Other Noncurrent Operating Assets		 3.51 3.12 2.91 2.70 2.26 2.03 1.79 0.88 0.63 0.36 1.32
Total Liabilities & Shareholders' Equity		 137 98 133 107 250 441 416 479 453 396 1,460
Total Liabilities		 32 34 28 20 21 22 34 40 49 53 50
Total Current Liabilities		 29 30 24 17 19 21 33 40 49 53 50
Accounts Payable		 10 17 8.01 7.17 9.40 8.20 15 23 29 31 31
Accrued Expenses		 18 9.35 13 6.98 6.98 10 15 16 19 22 18
Other Current Liabilities		 0.98 1.04 1.06 1.10 1.16 1.19 1.22 1.07 0.76 0.44 1.44
Total Noncurrent Liabilities		 2.76 4.00 3.44 3.18 1.93 1.34 0.73 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 105 64 106 87 230 419 383 439 404 344 1,410
Total Preferred & Common Equity		 105 64 106 87 230 419 383 439 404 344 1,410
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 105 64 106 87 230 419 383 439 404 344 1,410
Common Stock		 595 633 708 714 923 1,145 1,159 1,345 1,381 1,394 2,644
Retained Earnings		 -489 -568 -602 -627 -693 -726 -778 -906 -977 -1,051 -1,233
Accumulated Other Comprehensive Income / (Loss)		 -0.54 -0.02 0.00 0.00 0.00 -0.07 1.33 0.66 0.40 0.50 -1.59

Annual Metrics And Ratios for Praxis Precision Medicines

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 249.53% -100.00%
EBITDA Growth		 0.00% -72.80% -167.19% -28.80% 42.24% -52.67% -63.61%
EBIT Growth		 0.00% -72.76% -170.64% -27.91% 42.40% -48.30% -65.88%
NOPAT Growth		 0.00% -73.15% -170.03% -28.48% 41.22% -58.39% -62.96%
Net Income Growth		 0.00% -74.08% -170.24% -28.11% 42.40% -48.30% -65.88%
EPS Growth		 0.00% 70.45% 49.87% -28.11% 73.17% 45.37% -32.03%
Operating Cash Flow Growth		 0.00% -57.46% -136.69% -48.56% 39.94% -18.55% -89.04%
Free Cash Flow Firm Growth		 0.00% 0.00% -159.92% -49.44% 33.06% -26.14% -60.15%
Invested Capital Growth		 0.00% -94.62% -174.28% 2.85% 52.30% -107.02% -99.15%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 26.66% 432.90% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% -24.46% 7.70% 10.30% -21.56% -10.65%
EBIT Q/Q Growth		 0.00% 0.00% -24.70% 7.82% 10.39% -21.06% -11.07%
NOPAT Q/Q Growth		 0.00% 0.00% -24.52% 7.41% 9.75% -22.04% -11.29%
Net Income Q/Q Growth		 0.00% 0.00% -24.50% 7.52% 10.39% -21.06% -11.07%
EPS Q/Q Growth		 0.00% 0.00% -30.46% 7.52% -22.80% -27.63% -8.53%
Operating Cash Flow Q/Q Growth		 0.00% -24.26% -24.65% 7.98% 4.26% -32.42% -8.83%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.90% 1.03% -26.87% -8.74%
Invested Capital Q/Q Growth		 0.00% 0.00% -36.05% -31.25% 18.83% 15.54% -5.02%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -5,018.31% -2,191.87% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -5,164.41% -2,340.29% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -5,037.88% -2,137.48% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -5,037.88% -2,137.48% 0.00%
Tax Burden Percent		 99.76% 99.99% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.46% 100.00% 99.84% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -88.53% -37.74% -62.07% -130.94% -169.13% -70.98% -45.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -121.41% -64.03% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -121.41% -64.03% 0.00%
Return on Common Equity (ROCE)		 178.79% -23.79% -62.07% -130.94% -169.13% -70.98% -45.83%
Return on Equity Simple (ROE_SIMPLE)		 43.84% -21.51% -66.61% -281.22% -176.95% -41.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -43 -117 -150 -88 -140 -228
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -3,615.08% -1,638.20% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -23.34% -10.80% -17.44% -33.76% -38.30% -15.51% -10.74%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -126.97% -31.45% -26.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 1,718.59% 658.31% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 3,545.81% 1,781.98% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 5,264.41% 2,440.29% 0.00%
Earnings before Interest and Taxes (EBIT)		 -36 -62 -167 -214 -123 -183 -303
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -62 -165 -213 -123 -187 -307
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 7.32 3.52 1.47 2.74 3.22 8.39
Price to Tangible Book Value (P/TBV)		 0.00 7.32 3.52 1.47 2.74 3.22 8.39
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 78.03 167.70 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 44.81 112.81 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.04 -1.06 -1.15 -1.25 -1.07 -1.05
Leverage Ratio		 1.19 1.07 1.11 1.25 1.39 1.11 1.07
Compound Leverage Factor		 1.18 1.07 1.11 1.25 1.39 1.11 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 301.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -201.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.25 80.12 10.26 -10.07 -7.80 20.11 71.93
Noncontrolling Interest Sharing Ratio		 301.95% 36.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 6.67 19.23 7.48 3.23 5.39 10.77 10.22
Quick Ratio		 6.57 18.87 7.18 2.93 5.16 10.45 10.03
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -39 -101 -151 -101 -128 -204
Operating Cash Flow to CapEx		 -32,446.60% 0.00% -11,862.29% -41,676.35% -222,272.00% 0.00% -444,764.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.02 0.03 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 3.14 20.91 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -4.70 -9.15 -25 -24 -12 -24 -48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.14 -0.48 0.00
Increase / (Decrease) in Invested Capital		 0.00 -4.45 -16 0.72 13 -12 -24
Enterprise Value (EV)		 217 1,809 608 12 110 965 6,445
Market Capitalization		 141 2,105 884 112 191 1,434 7,371
Book Value per Share		 ($52.96) $7.51 $5.59 $1.62 $0.54 $23.90 $35.12
Tangible Book Value per Share		 ($52.96) $7.51 $5.59 $1.62 $0.54 $23.90 $35.12
Total Capital		 40 287 251 76 70 445 878
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -45 -297 -276 -100 -81 -470 -926
Capital Expenditures (CapEx)		 0.10 0.00 1.05 0.44 0.05 0.00 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.14 -10 -27 -24 -12 -26 -48
Debt-free Net Working Capital (DFNWC)		 39 287 249 76 69 367 551
Net Working Capital (NWC)		 39 287 249 76 69 367 551
Net Nonoperating Expense (NNE)		 10 18 50 64 35 43 75
Net Nonoperating Obligations (NNO)		 -45 -297 -276 -100 -81 -470 -926
Total Depreciation and Amortization (D&A)		 0.04 0.05 2.27 1.42 0.48 -4.65 -3.45
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -497.30% -301.01% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 2,825.13% 4,288.81% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 2,825.13% 4,288.81% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($117.90) ($59.10) ($69.60) ($18.69) ($10.21) ($13.48)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.57M 2.83M 3.07M 6.59M 17.91M 22.50M
Adjusted Diluted Earnings per Share		 $0.00 ($117.90) ($59.10) ($69.60) ($18.69) ($10.21) ($13.48)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.57M 2.83M 3.07M 6.59M 17.91M 22.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($117.90) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 596.68K 3.03M 3.49M 13.24M 20.16M 27.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -43 -117 -150 -88 -140 -228
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -3,615.08% -1,638.20% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -5,037.88% -2,137.48% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.34% -0.12% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Praxis Precision Medicines

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 27,850,833.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 27,850,833.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -3.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -36.90% -54.29% -35.47% 1,349.13% -100.00% -100.00% -100.00% 0.00% 0.00%
EBITDA Growth		 43.80% 34.51% -5.95% 0.30% -119.48% -124.24% -78.31% -111.34% -38.64% -49.20% -32.21%
EBIT Growth		 43.95% 34.72% -5.60% 4.77% -110.74% -118.32% -75.20% -117.67% -42.43% -51.52% -33.57%
NOPAT Growth		 42.39% 32.92% -9.96% -7.23% -122.74% -130.01% -78.41% -102.91% -37.87% -51.74% -41.66%
Net Income Growth		 43.95% 34.72% -5.60% 4.77% -110.74% -118.32% -75.20% -117.67% -42.43% -51.52% -33.57%
EPS Growth		 43.95% 69.55% 73.16% 76.42% -1.10% 19.61% -15.85% -90.23% -22.18% -20.43% 2.74%
Operating Cash Flow Growth		 48.32% 17.17% 36.50% 12.61% -18.46% -135.20% -154.16% -100.44% -136.57% -36.00% -62.52%
Free Cash Flow Firm Growth		 28.39% -8.35% -0.72% 6.64% -15.82% -0.33% 10.69% 15.33% -47.22% -36.31% -108.63%
Invested Capital Growth		 22.87% 52.30% 36.28% 21.12% -98.95% -107.02% -141.14% -187.96% -60.17% -99.15% -15.34%
Revenue Q/Q Growth		 -40.08% 10.04% -16.31% -17.17% -15.41% 2,371.19% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 28.30% -9.15% -47.66% 13.72% -57.83% -11.52% -17.42% -2.26% -3.54% -20.01% -4.05%
EBIT Q/Q Growth		 28.21% -9.12% -47.16% 17.38% -58.86% -13.04% -18.09% -2.64% -3.95% -20.26% -4.11%
NOPAT Q/Q Growth		 27.01% -8.97% -50.64% 10.50% -51.61% -12.53% -16.84% -1.79% -3.01% -23.85% -9.08%
Net Income Q/Q Growth		 28.21% -9.12% -47.16% 17.38% -58.86% -13.04% -18.09% -2.64% -3.95% -20.26% -4.11%
EPS Q/Q Growth		 28.21% -50.00% 30.39% 38.73% -58.05% -19.27% -0.30% -0.61% -1.51% -17.56% 18.99%
Operating Cash Flow Q/Q Growth		 25.63% -2.78% 12.59% -30.79% -0.81% -104.08% 5.55% -3.14% -18.99% -17.32% -12.88%
Free Cash Flow Firm Q/Q Growth		 31.62% -45.71% -15.06% 18.57% 15.17% -26.23% -2.43% 22.80% -47.50% -16.87% -56.77%
Invested Capital Q/Q Growth		 23.27% 18.83% -16.98% -8.27% -93.52% 15.54% -36.26% -29.29% -7.64% -5.02% 21.08%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -5,239.96% -5,197.48% -9,170.53% -9,552.10% -17,822.19% -804.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -5,452.14% -5,399.22% -9,718.33% -10,500.84% -18,819.54% -856.97% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -5,263.25% -5,219.03% -9,177.03% -9,153.22% -17,188.74% -786.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -5,263.25% -5,219.03% -9,177.03% -9,153.22% -17,188.74% -786.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -143.36% -169.13% -85.25% -47.16% -64.34% -70.98% -63.56% -60.98% -75.20% -45.83% -35.32%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -83.48% -125.78% -115.50% -56.43% -105.50% -23.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -83.48% -125.78% -115.50% -56.43% -105.50% -23.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -143.36% -169.13% -85.25% -47.16% -64.34% -70.98% -63.56% -60.98% -75.20% -45.83% -35.32%
Return on Equity Simple (ROE_SIMPLE)		 -158.57% 0.00% -54.59% -29.53% -39.46% 0.00% -48.40% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -19 -29 -26 -40 -45 -52 -53 -55 -68 -74
NOPAT Margin		 -3,816.50% -3,779.46% -6,802.83% -7,350.59% -13,173.68% -599.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.02% -8.16% -6.22% -2.31% -4.73% -5.05% -4.75% -4.06% -4.77% -3.01% -1.92%
Return On Investment Capital (ROIC_SIMPLE)		 - -27.94% - - - -10.05% -11.91% -13.17% -15.97% -7.74% -5.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,864.10% 1,928.74% 3,557.54% 2,964.99% 5,051.66% 202.75% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 3,688.03% 3,570.49% 6,260.79% 7,635.85% 13,867.88% 754.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 5,552.14% 5,499.22% 9,818.33% 10,600.84% 18,919.54% 956.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -27 -40 -33 -52 -59 -69 -71 -74 -89 -93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -27 -40 -34 -54 -60 -70 -72 -75 -90 -93
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.53 2.74 3.52 1.69 2.67 3.22 1.74 2.12 3.25 8.39 6.36
Price to Tangible Book Value (P/TBV)		 2.53 2.74 3.52 1.69 2.67 3.22 1.74 2.12 3.25 8.39 6.36
Price to Revenue (P/Rev)		 113.77 78.03 368.02 399.54 636.60 167.70 94.01 110.30 149.46 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 61.45 44.81 257.18 154.57 380.42 112.81 35.90 52.78 97.31 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.17 -1.25 -1.12 -1.06 -1.09 -1.07 -1.07 -1.07 -1.10 -1.05 -1.04
Leverage Ratio		 1.27 1.39 1.19 1.10 1.11 1.11 1.09 1.09 1.12 1.07 1.05
Compound Leverage Factor		 1.27 1.39 1.19 1.10 1.11 1.11 1.09 1.09 1.12 1.07 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.39 -4.18 19.92 17.70 16.17 20.96 9.22 7.73 9.02 72.68 106.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.15 5.39 11.27 17.30 10.96 10.77 8.44 6.31 5.18 10.22 15.88
Quick Ratio		 6.02 5.16 11.04 17.06 10.86 10.45 8.30 6.20 5.05 10.03 15.66
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -32 -37 -30 -26 -32 -33 -26 -38 -44 -69
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -82,828.13% 0.00% 0.00% 0.00% -138,954.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.01 0.01 0.01 0.03 0.02 0.02 0.02 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.17 3.14 3.27 3.14 3.29 20.91 22.47 24.77 33.10 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -14 -12 -14 -15 -29 -24 -33 -42 -46 -48 -38
Invested Capital Turnover		 -0.12 -0.14 -0.13 -0.11 -0.07 -0.48 -0.35 -0.27 -0.20 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.25 13 7.75 3.94 -14 -12 -19 -28 -17 -24 -5.03
Enterprise Value (EV)		 119 110 565 274 611 965 292 410 726 6,445 7,525
Market Capitalization		 220 191 808 708 1,022 1,434 764 857 1,115 7,371 8,973
Book Value per Share		 $0.67 $0.54 $17.35 $24.50 $21.55 $23.90 $21.78 $19.85 $16.32 $35.12 $50.63
Tangible Book Value per Share		 $0.67 $0.54 $17.35 $24.50 $21.55 $23.90 $21.78 $19.85 $16.32 $35.12 $50.63
Total Capital		 87 70 230 419 383 445 439 404 344 878 1,410
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -101 -81 -243 -434 -411 -470 -472 -447 -389 -926 -1,448
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 -0.01 0.00 0.00 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -12 -14 -16 -30 -26 -34 -43 -46 -48 -39
Debt-free Net Working Capital (DFNWC)		 87 69 193 336 327 367 294 258 221 551 748
Net Working Capital (NWC)		 87 69 193 336 327 367 294 258 221 551 748
Net Nonoperating Expense (NNE)		 6.77 7.41 10 6.44 12 14 17 18 19 21 18
Net Nonoperating Obligations (NNO)		 -101 -81 -243 -434 -411 -470 -472 -447 -389 -926 -1,448
Total Depreciation and Amortization (D&A)		 0.11 0.11 0.03 -1.42 -1.91 -1.34 -1.18 -0.94 -0.69 -0.64 -0.62
Debt-free, Cash-free Net Working Capital to Revenue		 -753.11% -497.30% -656.31% -891.19% -1,859.50% -301.01% -417.85% -557.68% -619.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 4,479.04% 2,825.13% 8,793.17% 18,977.75% 20,385.48% 4,288.81% 3,620.45% 3,322.23% 2,960.75% 0.00% 0.00%
Net Working Capital to Revenue		 4,479.04% 2,825.13% 8,793.17% 18,977.75% 20,385.48% 4,288.81% 3,620.45% 3,322.23% 2,960.75% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.70) ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20)
Adjusted Weighted Average Basic Shares Outstanding		 9.04M 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M
Adjusted Diluted Earnings per Share		 ($2.70) ($4.08) ($2.84) ($1.74) ($2.75) ($3.28) ($3.29) ($3.31) ($3.36) ($3.95) ($3.20)
Adjusted Weighted Average Diluted Shares Outstanding		 9.04M 6.59M 13.90M 18.82M 18.88M 17.91M 21.06M 21.47M 21.98M 22.50M 28.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.08) $0.00 $0.00 $0.00 ($3.28) $0.00 $0.00 $0.00 ($3.95) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.57M 13.24M 17.11M 17.76M 18.64M 20.16M 20.37M 21.05M 25.01M 27.85M 27.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -19 -29 -26 -40 -45 -52 -53 -55 -68 -74
Normalized NOPAT Margin		 -3,816.50% -3,779.46% -6,802.83% -7,350.59% -13,173.68% -599.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -5,263.25% -5,219.03% -9,177.03% -9,153.22% -17,188.74% -786.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Praxis Precision Medicines (PRAX) has been operating as a clinical-stage biotech with little to no revenue in the 2025 periods. The company has relied heavily on equity financing to fund ongoing operations and investments. Below are the standout trends from the last four years of quarterly statements.

  • Q4 2025 equity financing: issuance of common stock raised about $613.3 million, greatly boosting the company’s cash runway.
  • Q4 2025 financing cash inflow: Net cash from financing activities was about $612.5 million, highlighting strong access to capital markets to fund operations and investments.
  • Liquidity in mid-2025: Cash and short-term investments on the balance sheet hovered around $267 million (roughly $149.5 million in cash and $117.6 million in short-term investments in Q3 2025), providing a substantial liquidity cushion for ongoing trials and expenses.
  • Long-term investments: The balance sheet shows meaningful long-term investments (approximately $122 million in Q3 2025, with similar levels in adjacent quarters), adding diversification of assets and potential value realization options.
  • Strong equity base relative to liabilities: Total Common Equity was about $343.5 million in Q3 2025, with modest total liabilities (roughly $52.9 million), indicating a solid equity cushion to fund future activity.
  • No revenue in 2025 quarters: Total revenue remains at zero for Q1–Q4 2025, consistent with Praxis’ clinical-stage business model and lack of product revenue so far.
  • High research and development costs: R&D expenses remain a major cost driver (for example, about $77.5 million in Q4 2025; $65.8 million in Q3 2025), contributing to continued operating losses.
  • Persistent net losses: Net income (or loss) across the more recent quarters shows substantial negative figures (e.g., -$88.9 million in Q4 2025; -$73.9 million in Q3 2025), underscoring ongoing burn before profitability.
  • Investing cash outflows focused on investments: Net cash from continuing investing activities is negative in several quarters (Q4 2025 shows a large outflow from purchases of investments, around -$328.4 million), indicating significant allocation to investing activities beyond core operations.
  • Operating cash flow is negative and widening: Net cash from operating activities was substantial negative across recent quarters (for example, about -$77.4 million in Q4 2025 and -$65.1 million in Q3 2025), signaling ongoing cash burn that requires external financing to sustain operations.
05/18/26 10:05 PM ETAI Generated. May Contain Errors.

Praxis Precision Medicines Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Praxis Precision Medicines' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Praxis Precision Medicines' net income appears to be on an upward trend, with a most recent value of -$303.27 million in 2025, rising from -$35.51 million in 2019. The previous period was -$182.82 million in 2024. Find out what analysts predict for Praxis Precision Medicines in the coming months.

Praxis Precision Medicines' total operating income in 2025 was -$326.20 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $326.20 million

Over the last 6 years, Praxis Precision Medicines' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Praxis Precision Medicines' total liabilities were at $59.77 million at the end of 2025, a 58.7% increase from 2024, and a 688.4% increase since 2019.

In the past 6 years, Praxis Precision Medicines' cash and equivalents has ranged from $44.82 million in 2019 to $357.33 million in 2025, and is currently $357.33 million as of their latest financial filing in 2025.

Over the last 6 years, Praxis Precision Medicines' book value per share changed from -52.96 in 2019 to 35.12 in 2025, a change of -166.3%.


Related Companies

Financial statements for NASDAQ:PRAX last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
They're not telling you how bad this could get
Valuations are stretched to levels seen only a handful of times in the last hundred years — yet most retiremen...
Parkview Capital Group | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel